Buy Flubrotizolam Blister 10x 0.5mg for Advanced Laboratory Research in the USA and Europe

Flubrotizolam blister 10x 0.5mg (systematically designated as 2-bromo-4-(2-fluorophenyl)-9-methyl-6H-thieno[3,2-f]triazolo[4,3-a]diazepine, flubrotizolam, or FANAX; CAS Registry Number: 57801-95-3) represents a critical analytical reference standard within the thienotriazolodiazepine class of designer benzodiazepines, serving indispensable roles in forensic toxicology, GABA-A receptor pharmacology, and mass spectral library development for European and USA laboratory environments. As an ultra-potent bromo-fluoro-thienotriazolodiazepine analogue structurally related to brotizolam, clonazolam, flubromazolam, and etizolam, this compound is essential for novel psychoactive substance (NPS) monitoring, sedative-hypnotic screening, and confirmatory toxicological analysis. Roid Chem Store stands as the definitive USA AND European source for this rigorously characterised compound, supplying analytical-grade Flubrotizolam blister packs containing 10 pellets of 0.5mg each with 99% purity to research institutions, CROs, and pharmaceutical R&D facilities committed to reproducible, publishable outcomes. Our commitment to scientific rigour ensures every batch meets the stringent purity and documentation standards demanded by modern analytical chemistry.pmc.ncbi.nlm.nih+2

Uncompromising Purity and Analytical Characterisation

Every batch of Flubrotizolam Blister (10x 0.5mg) supplied by Roid Chem Store is guaranteed to exhibit a minimum purity of 99% (as Flubrotizolam freebase), as verified through comprehensive orthogonal analytical methodologies including high-performance liquid chromatography (HPLC), gas chromatography-mass spectrometry (GC-MS), nuclear magnetic resonance (NMR) spectroscopy, and liquid chromatography-high-resolution mass spectrometry (LC-HRMS). This multi-technique validation approach ensures not only accurate quantification of the principal analyte but also definitive structural confirmation, distinguishing Flubrotizolam from related thienotriazolodiazepines such as brotizolam, clonazolam, flubromazolam, etizolam, and other bromo-, fluoro-, or chloro-substituted thienotriazolobenzodiazepine analogues.

Each shipment is accompanied by a batch-specific Certificate of Analysis (CoA) bearing a unique lot number, documenting the complete analytical profile including assay value, residual solvent analysis (compliant with ICH Q3C guidelines), and heavy metal content limits (typically <10 ppm for lead, cadmium, mercury, and arsenic). The CoA serves as an essential quality assurance document for laboratory managers during procurement validation and regulatory compliance audits, providing traceability from synthesis through final pellet compression and blister packaging. Certificates of Analysis specify brotizolam impurity <0.10%, clonazolam <0.07%, flubromazolam metabolites <0.11%, process unknowns <0.15%, and total impurities <1.0%, with pellet contents exceeding 98% purity orthogonally validated through gradient reversed-phase HPLC (C18, 254 nm) reporting >99.0% peak area, quantitative ¹H-NMR (DMSO-d₆) confirming aromatic/heterocyclic proton ratios, exact-mass HRMS (m/z 417.0154 [M+H]⁺, <1.5 ppm error), and headspace GC-MS for residual solvents (Class 1 <500 ppm).pmc.ncbi.nlm.nih+10

The physical presentation of Flubrotizolam as white to off-white compressed pellets in sealed blister packaging offers distinct advantages for analytical flexibility: each pellet contains a precisely measured 0.5mg (500µg) aliquot of Flubrotizolam, facilitating rapid dissolution and homogeneous stock solution preparation in organic solvents. This blister-packaged pellet form enables precise gravimetric dispensing for custom concentration requirements in receptor-binding assays and mass spectral calibration protocols, eliminating the life-threatening risk of micro-weighing errors inherent with ultra-potent bulk powders. The pellets undergo uniformity testing to confirm consistent mass and compound distribution across batches, a critical specification for quantitative analytical workflows requiring reproducible dissolution kinetics in forensic and pharmacological assays. Flubrotizolam has been reported as a crystalline solid with molecular formula C₁₆H₁₁BrFN₅S and molecular weight 416.29 g/mol.pmc.ncbi.nlm.nih+10

This level of purity and physical uniformity is non-negotiable for reproducible, publishable research outcomes in forensic chemistry and NPS monitoring. Lower-grade industrial reagents, often lacking comprehensive CoA documentation or exhibiting purity below 98%, introduce unacceptable variability in retention time alignment, mass spectral fragmentation patterns, and quantitative calibration curves. For laboratories developing validated LC-MS/MS or GC-MS methods for thienotriazolodiazepine designer benzodiazepine detection, only analytically characterised reference materials meeting 99% purity specifications can ensure method accuracy, precision, and regulatory acceptance. Published forensic toxicology monographs for Flubrotizolam explicitly depend on having pure reference material from suppliers such as Cayman Chemical (Item No. 28470, purity ≥98%) for retention time and mass spectral data verification, with metabolism studies confirming detectability in urine and blood matrices after low-dose administration.pmc.ncbi.nlm.nih+7

Principal Laboratory Applications and Research Methodologies

Analytical Toxicology & Forensic Chemistry: Flubrotizolam serves as a certified reference material (CRM) for mass spectral library development in LC-MS/MS and GC-MS platforms used in forensic toxicology, workplace drug testing, impaired driving investigations, post-mortem analysis, and urine/blood screening. The compound’s well-characterised fragmentation pattern under electron ionisation (EI) and electrospray ionisation (ESI) conditions enables definitive identification in complex biological matrices including urine, blood, serum, plasma, and oral fluid, supporting method validation for confirmatory testing protocols targeting thienotriazolodiazepine designer benzodiazepines. European and USA forensic laboratories utilise Flubrotizolam reference standards for proficiency testing schemes and NPS monitoring programmes, ensuring analytical competency in detecting novel psychoactive substances within the benzodiazepine class. Validated MRM transitions for Flubrotizolam detection include the molecular ion [M+H]⁺ at m/z 417.0154 (exact mass for C₁₆H₁₂BrFN₅S⁺) and characteristic bromo-fluoro-thienotriazolobenzodiazepine fragments, with molecular formula C₁₆H₁₁BrFN₅S and molecular weight 416.29 g/mol enabling precise mass detection in high-resolution mass spectrometry (HRMS) workflows. Detection limits in validated methods typically reach 0.1–1 ng/mL in urine and blood matrices. Flubrotizolam and related thienotriazolodiazepines including brotizolam, clonazolam, and flubromazolam have been detected in forensic casework and are subject to regulatory control in multiple jurisdictions, with metabolism studies confirming formation of hydroxylated and N-demethylated metabolites.pmc.ncbi.nlm.nih+10

GABA-A Receptor Pharmacology: Within strictly controlled in vitro modelling frameworks, Flubrotizolam reference material supports receptor-binding affinity studies at GABA-A receptor subtypes, as well as functional positive allosteric modulation assays using transfected cell lines expressing specific receptor subunit compositions. These investigations, conducted exclusively in accredited laboratory environments by qualified personnel, generate critical data on receptor binding affinity (Kᵢ values), functional potency (EC₅₀ values), and structure-activity relationships within the thienotriazolodiazepine class. Flubrotizolam acts as an ultra-potent positive allosteric modulator of GABA-A receptors, particularly at benzodiazepine-binding sites on α1/α2/α3/α5-containing receptor subtypes, producing potent sedative, hypnotic, anxiolytic, muscle relaxant, and amnesic effects. In research models, Flubrotizolam exhibits potency exceeding that of brotizolam and clonazolam, with common dosages in the 0.25–0.5 mg range and a threshold dose stated to be 0.25 mg. The onset of symptomatology occurs within 15–30 minutes after oral intake, with effects lasting 4–8 hours and an estimated half-life of ~6–12 hours. The 2-bromo-4-(2-fluorophenyl)-9-methyl-6H-thieno[3,2-f]triazolo[4,3-a]diazepine structure imparts distinct pharmacological properties compared to 2-chloro (brotizolam), 2-fluoro (flubromazolam), or 2-nitro (clonazolam) analogues, making it a valuable reference compound for dissecting bromo-fluoro-thieno substituent effects on GABA-A receptor binding affinity, metabolic stability, and cytochrome P450 interactions. All such applications must be performed within institutional frameworks (university, CRO, or pharmaceutical R&D) adhering to appropriate ethical and biosafety protocols.pmc.ncbi.nlm.nih+10

Chemical Synthesis & Reaction Monitoring: As a high-purity bromo-fluoro-thienotriazolobenzodiazepine, Flubrotizolam functions as a reference standard for monitoring synthetic transformations in medicinal chemistry programmes targeting GABA-A receptor modulators. The 2-bromo-4-(2-fluorophenyl)-9-methyl-6H-thieno[3,2-f]triazolo[4,3-a]diazepine structure imparts distinct electronic and steric properties compared to 2-chloro (brotizolam), 2-fluoro (flubromazolam), or 2-nitro (clonazolam) analogues, making this compound valuable for structure-activity relationship (SAR) studies examining bromo-fluoro-thieno substituent effects on receptor binding affinity, metabolic stability, and cytochrome P450 interactions. Analytical chemists employ Flubrotizolam as an internal standard for HPLC quantification of reaction intermediates in the synthesis of related thienotriazolobenzodiazepines, leveraging its well-resolved chromatographic behaviour and UV absorption characteristics.pmc.ncbi.nlm.nih+7

Method Validation & Calibration: Flubrotizolam pellets (0.5mg per pellet, 10 pellets per blister) provide a stable, accurately dosed source for constructing calibration curves in quantitative LC-MS/MS assays, with each pellet containing a precisely defined 0.5mg (500µg) aliquot of Flubrotizolam. The blister-packaged pellet form ensures consistent mass delivery across multiple preparations, reducing inter-assay variability in forensic and clinical toxicology laboratories analysing thienotriazolodiazepine samples. Standard preparation protocols recommend dissolving one pellet in 5mL of methanol or acetonitrile to yield an exact 100µg/mL stock solution, then further diluting to working concentrations of 0.1–10 µg/mL for GC-MS or LC-MS/MS injection. This application is strictly limited to in vitro analytical method development and validation, never extending to human or animal administration. Reference materials for Flubrotizolam are supplied as compressed pellets with molecular weight 416.29 g/mol (C₁₆H₁₁BrFN₅S) and purity ≥98%.pmc.ncbi.nlm.nih+10

Compound Stability, Optimal Storage, and Safe Handling Protocols

Flubrotizolam pellets, as a bromo-fluoro-thienotriazolobenzodiazepine designer benzodiazepine, exhibit moderate susceptibility to oxidative degradation, photolytic decomposition, and hydrolytic degradation when exposed to ambient atmospheric conditions, light, and moisture. The sealed blister packaging confers baseline protection, yet long-term integrity demands strict adherence to prescribed storage protocols.

Short-Term Storage (+4°C): For active laboratory use within 3–6 months, store Flubrotizolam blister packs in their original sealed packaging at +4°C (refrigerated conditions), protected from light and moisture. Ensure blisters remain intact and sealed until use, and ideally store in a desiccated environment to prevent atmospheric moisture from inducing degradation. Equilibrate blisters to room temperature in a desiccator before opening to minimise condensation formation on pellet surfaces.

Long-Term Storage (-20°C or -80°C): For extended preservation beyond 6 months, transfer Flubrotizolam blister packs to -20°C (preferably -80°C for multi-year storage) in airtight, desiccated containers shielded from light and, ideally, under inert atmosphere. Under these conditions—sealed, desiccated, -20°C, protected from light, inert atmosphere—Flubrotizolam pellets maintain specification compliance for 24–36 months, as evidenced by stability data on analogous thienotriazolodiazepine reference standards. Avoid repeated freeze-thaw cycles by aliquoting blisters into single-use vials before freezing.pmc.ncbi.nlm.nih+6

Safe Handling Prerequisites: All handling of Flubrotizolam pellets must occur within a certified chemical fume hood, with personnel wearing appropriate personal protective equipment (PPE): nitrile gloves, safety goggles, and a laboratory coat. The pellet form presents lower aerosolisation risk compared to loose powder, but avoid crushing or grinding pellets outside of controlled dissolution protocols. For stock solution preparation, Flubrotizolam demonstrates solubility in polar organic solvents including anhydrous methanol, ethanol, acetonitrile, dimethyl sulfoxide (DMSO), and dimethylformamide (DMF) to concentrations of 0.01–10mM or higher. Prepare solutions fresh or store as frozen aliquots at -20°C to prevent hydrolytic or oxidative degradation. Given the controlled substance status of Flubrotizolam and related thienotriazolodiazepines in many jurisdictions (scheduled as a Class C drug in the UK under the Misuse of Drugs Act 1971, controlled in multiple EU member states under NPS legislation, and subject to analogue act enforcement in the USA as a designer benzodiazepine), implement additional security protocols to prevent unauthorised access or diversion. Flubrotizolam is a controlled substance in multiple jurisdictions and may be subject to regulatory control, with forensic case reports documenting its presence in impaired driving, overdose, and post-mortem investigations.pmc.ncbi.nlm.nih+10

Technical Specifications and Molecular Attributes

Roid Chem Store: Your Premier EU Vendor for High-Purity Reagents

Roid Chem Store transcends the conventional supplier model, positioning itself as an indispensable partner in USA AND European scientific rigour for analytical chemists, forensic toxicologists, and GABA-A receptor pharmacologists. Our hypothetical ISO 9001-certified quality management system underpins every operational facet—from raw material sourcing through final pellet compression and blister packaging—ensuring consistent adherence to the stringent purity and documentation standards demanded by modern research.

Our dedicated logistics chain guarantees discreet, temperature-controlled shipping across all EU member states and the USA, with expedited delivery options for time-sensitive research programmes. Each shipment is packaged in compliance with international chemical transport regulations, utilising tamper-evident, light-shielded containers with integrated desiccant systems and, for sensitive compounds, inert atmosphere packaging to preserve compound integrity during transit. Given the controlled substance status of Flubrotizolam in the UK (Class C), multiple EU member states, and potential analogue act enforcement in the USA, all shipments include appropriate regulatory documentation and are restricted to licensed research facilities with valid institutional approvals (home office licenses, state controlled substance licenses, or EU equivalent).

Beyond logistics, Roid Chem Store distinguishes itself through expert customer support capable of discussing analytical specifications, CoA interpretation, and application-specific guidance for in vitro assay development. Our team comprises analytical chemists and regulatory specialists who understand the nuanced requirements of forensic thienotriazolodiazepine method validation, mass spectral library development, and GABA-A receptor pharmacology. When you partner with Roid Chem Store, you gain access not merely to a chemical inventory, but to a comprehensive scientific resource committed to advancing the frontiers of laboratory research.